Search
Interleukin-17 receptor A
go.drugbank.com/bio_entities/BE0018249TargetHumansReceptor for IL17A (PubMed:17911633, PubMed:9367539). Receptor for IL17F (PubMed:17911633, PubMed:19838198). Binds to IL17A with higher affinity than to IL17F (PubMed:17911633). … Receptor for IL17C as part of a heterodimeric complex with IL17RE (PubMed:21993848)
Polypeptides: Interleukin-17 receptor ASynonyms: IL-17 receptor AInterleukin-17 receptor B
go.drugbank.com/bio_entities/BE0020027TargetHumansReceptor for the pro-inflammatory cytokines IL17B and IL17E. May play a role in controlling the growth and/or differentiation of hematopoietic cells
Polypeptides: Interleukin-17 receptor BSynonyms: IL-17 receptor B, IL-17B receptorInsulin receptor substrate 2
go.drugbank.com/bio_entities/BE0021286TargetHumansSignaling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R (PubMed:25879670 … Upon phosphorylation by the insulin receptor, functions as a signaling scaffold that propagates insulin action through binding to SH2 domain-containing proteins including the p85 regulatory subunit of
Polypeptides: Insulin receptor substrate 2Capsaicin
go.drugbank.com/drugs/DB06774ApprovedInvestigationalThe most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersProducts: Capzasin-P Creme - 0.025%, Capzasin P Arthritis Pain ReliefDaprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigationalDaprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK. Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent in...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsInsulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalThe resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4 allowing for the slow release of small amounts of insulin glargine, giving the drug a long duration of action
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersSonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigational[L56193,A275521] Sonrotoclax was rationally designed as a BH3 mimetic with a shallow and broad interaction with the P2 pocket of BCL-2, achieved through a novel 7-azaspiro[3.5]nonane linker; this binding
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPolysorbate 80
go.drugbank.com/drugs/DB11063ApprovedInvestigationalPolysorbate, a substance formulated by the reaction of sorbitan fatty acid ester (a nonionic surfactant) with ethylene oxide, is used in many foreign countries, including the U.S. and the EU, where it acts as an emulsifier, a solubilizer...
Mixtures: Refresh Digital PFCategories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsTelmisartan
go.drugbank.com/drugs/DB00966ApprovedInvestigational[A1489,A1490] Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.[A1492] … Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Enzyme InhibitorsDosulepin
go.drugbank.com/drugs/DB09167ApprovedInvestigationalDosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors